U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C22H24ClN5O2
Molecular Weight 425.911
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DOMPERIDONE

SMILES

ClC1=CC2=C(C=C1)N(C3CCN(CCCN4C(=O)NC5=C4C=CC=C5)CC3)C(=O)N2

InChI

InChIKey=FGXWKSZFVQUSTL-UHFFFAOYSA-N
InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)

HIDE SMILES / InChI

Description

Domperidone is a peripherally selective D2 receptor antagonist. It acts as an antiemetic and a prokinetic agent through its effects on the chemoreceptor trigger zone and motor function of the stomach and small intestine. Domperidone was not approved in USA due to risks of cardiac arrhythmias, cardiac arrest, and sudden death, but is available in other countries. However, FDA allows access to Domperidone through an expanded access investigational new drug application (IND) to patients with gastroesophageal reflux disease with upper GI symptoms, gastroparesis, and chronic constipation. As an “off-label” use, domperidone is prescribed to breastfeeding women to enhance their milk production.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
1.0 nM [Ki]
3.5 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MOTILIUM
Primary
MOTILIUM
Primary
MOTILIUM
Primary
MOTILIUM

Cmax

ValueDoseCo-administeredAnalytePopulation
17.67 ng/mL
10 mg single, oral
DOMPERIDONE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
87.08 ng × h/mL
10 mg single, oral
DOMPERIDONE plasma
Homo sapiens
327 ng × h/mL
10 mg single, intravenous
DOMPERIDONE plasma
Homo sapiens
289 ng × h/mL
10 mg single, intramuscular
DOMPERIDONE plasma
Homo sapiens
57.7 ng × h/mL
10 mg single, oral
DOMPERIDONE plasma
Homo sapiens
259 ng × h/mL
60 mg single, oral
DOMPERIDONE plasma
Homo sapiens
243 ng × h/mL
60 mg single, rectal
DOMPERIDONE plasma
Homo sapiens
463 ng × h/mL
60 mg single, oral
DOMPERIDONE plasma
Homo sapiens
249 ng × h/mL
60 mg single, oral
DOMPERIDONE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
13.68 h
10 mg single, oral
DOMPERIDONE plasma
Homo sapiens
7.45 h
10 mg single, intravenous
DOMPERIDONE plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
5.5%
DOMPERIDONE plasma
Homo sapiens

Doses

AEs

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
Domperidone should be taken 15-30 minutes before meals and, if necessary, before retiring. Adult dose of the drug is 10 mg three times daily. Domperidone is also available as suppository or as a solution for intramuscular injection.
Route of Administration: Other
In Vitro Use Guide
After dissection, rat striata were homogenized by seven manual strokes in a Wheaton Teflon-glass homogenizer with ice cold 50 mM HEPES buffer, centrifuged at 27000g, the supernatant was discarded. The pellet was homogenized (five strokes), resuspended in ice cold buffer, and centrifuged again. Nonspecific binding of [3H]Spiperone (ca.0.07 nM) was defined by adding unlabeled chlorpromazine. Binding was terminated by filtering with 15 mL of ice cold buffer. Radioactivity was determined on an LKB-1219 Rack-Beta liquid scintillation counter. Domperidone binds to D2 receptorss with Ki of 1 nM